FDA Approves UPTRAVI — Actelion Pharmaceuticals US, Inc.

# FDA Approves Actelion Pharmaceuticals' UPTRAVI for Pulmonary Arterial Hypertension Actelion Pharmaceuticals US, Inc. received FDA approval for UPTRAVI (selexipag), an oral medication that expands the company's pulmonary arterial hypertension treatment portfolio and positions it to capture additional market share in the growing PAH therapeutic category. The approval of the first-in-class selective prostacyclin receptor agonist offers physicians a new oral monotherapy option, potentially strengthening Actelion's competitive position against existing PA